Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey,...
Transcript of Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey,...
![Page 1: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/1.jpg)
Update in Rheumatology 2015
Mary Beth Humphrey, MD, PhD, FACP
Professor of Medicine
Chief of Rheumatology, Immunology, and Allergy
University of Oklahoma Health Sciences Center
![Page 2: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/2.jpg)
Disclosures:
• I receive grant funds from NIH.
• I have no conflicts to disclose.
![Page 3: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/3.jpg)
Road map
• RA: Can we de-escalate therapy in patients in remission?
• Psoriatic arthritis: 1L-23 inhibitors, 1L-17 inhibitors, phosphodiesterase 4 inhibitors, CVD risk
• ANCA vasculitis: new treatment options
• Polymyalgia Rheumatic treatment guidelines
• Quick Pearls
![Page 4: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/4.jpg)
Rheumatic Disease in US
Osteoarthritis 15,800,000
RA 2,100,000
Gout 1,000,000
AS 318,000
Psoriatic Arthritis 160,000
SLE 131,000
JRA 71,000
![Page 5: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/5.jpg)
Rheumatoid Arthritis
Early Disease Late Disease
![Page 6: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/6.jpg)
RA Epidemiology
• Affects all ages
• Peaks in 40s to 60s
• 50% of patients diagnosed with RA will not be in the workforce in 10 years
• Women affected 2-4 times more than men
• More prevalent in Native American and Caucasian populations
![Page 7: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/7.jpg)
The Burden of Rheumatoid Arthritis
• Systemic inflammatory disease1
• Autoimmune etiology1
• Prevalence 1% in varied ethnic groups • 2 million people in the United States1
• Lifetime cost approaches that of cardiovascular diseases2
• Associated with an increased mortality risk3
1. Arthritis Foundation. At: http://www.arthritis.org/conditions/diseasecenter/RA/default.asp. Accessed June 4, 2007.
2. Kvien. Pharmacoeconomics. 2004;22(suppl 2):1.
3. Gabriel et al. Arthritis Rheum. 2003;48:54.
![Page 8: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/8.jpg)
Survival of Patients With Severe Rheumatoid Arthritis
*Defined as >20 actively inflamed joints.
Adapted with permission from Pincus et al. Ann Intern Med. 1999;131:768.
0
20
40
60
80
100
0 2 4 6 8 10
Su
rviv
al
(%)
≤10 joints 11-20 joints 21-30 joints >30 joints
Rheumatoid Arthritis (joint count)
0
20
40
60
80
100
0 2 4 6 8 10
Su
rviv
al
(%)
Coronary Artery Disease
Years
3-vessel disease
0
20
40
60
80
100
0 2 4 6 8 10
Su
rviv
al
(%)
Rheumatoid Arthritis (ADL scores)
>90% ADL “with ease” 81%-90% ADL “with ease” 71%-80% ADL “with ease” ≤70% ADL “with ease”
Hodgkin’s Disease
0
20
40
60
80
100
0 2 4 6 8 10
Su
rviv
al
(%)
Years
Stage IV
Years Years
1-vessel disease
2-vessel disease
Left main disease
Stage I
Stage II All cases, all stages Stage III
![Page 9: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/9.jpg)
Treatment Pyramid for RA: Treat Aggressively Early
Healey LA, Wilske KR. Rheum Dis Clin North Am. 1989;15:615-619.
Surgery
Multiple DMARDS: SSZ, HCQ, MTX, Prednisone
Add or substitute drugs Leflunomide
Add anti-TNF or other biologic
Change Biologic
![Page 10: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/10.jpg)
Approved Drugs for RA
TNF antagonists IL-6 antagonists Adalimumab Tocilizumab Etanercept Infliximab JAK inhibitors Golimumab Tofacitinib Certolizumab pegol
T cell inhibitor IL-1 antagonist Abatacept Anakinra
B-cell depletion Rituximab
Oral DMRADS Sulfasalazine
Hydroxychloroquine Methotrexate Leflunomide Azathioprine Cyclosporin
![Page 11: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/11.jpg)
Can We Sustain RA Remission and Taper DMARDS?
.
Emery P et al. N Engl J Med 2014;371:1781-1792.
![Page 12: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/12.jpg)
Half-dose Anti-TNF plus MTX is more effective for maintaining remission than MTX
Emery et al., NEJM 2014; 371:1781-92
![Page 13: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/13.jpg)
Psoriatic Arthritis Update in Therapies
![Page 14: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/14.jpg)
Psoriatic Arthritis (PsA)
• Men=Women
• Age of onset peaks in 4th and 5th decades
• Prevalence 1-2/1000 and 10-30% of Psoriasis patients
• Often seen with nail pitting, nail onycholysis, scalp or intergluteal lesions
• No association with severity of skin and risk of arthritis
• Associated with HLA-B27
![Page 15: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/15.jpg)
Role of IL-17 in the Pathogenesis of Psoriasis
![Page 16: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/16.jpg)
Drug Targets in the Pathogenesis of Psoriasis
Anti-TNFα Etanercept Adulimumab Infliximab Golimumab Certolizumab
Anti-IL-12/23 Ustekinumab
Anti-IL-17 Secukinumab
Anti-PDE4 Apremilast
PDE4 PDE4
![Page 17: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/17.jpg)
Secukinumab for Psoriatic Arthritis
Secukinumab (Stelara)
• Anti-IL 17 Receptor A
• Subcutaneous injections • 1 per week for 4 weeks
then q4weeks • Side effects:
infection, TB, non-melanoma skin cancer
ACR20
ACR50
McInnis et el. Lancet, 2015
![Page 18: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/18.jpg)
Brodalumab for psoriatic arthritis • Brodalumab
• Anti-IL-17 Receptor A • Subcutaneous q2 weeks
• Side effects: Infections Neutropenia
Mease et al. NEJM 2014:2295-2306
![Page 19: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/19.jpg)
Apremilast for Psoriatic Arthritis
Apremilast (Otezla) • Phosphodiesterase 4
(PDE4) inhibitor • 30mg orally BID (titrated up
from 10mg BID)
• Serious side effects: Weight loss (5-10% body mass)
Depression Suicides
Ann Rheum Dis. 2014; 73:1020-1026
![Page 20: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/20.jpg)
Psoriatic Arthritis Treatment Scheme
Psoriatic Arthritis
Skin & Nails
Peripheral Arthritis
Axial Arthritis
Enthesitis
Dactylitis
NSAIDS
Oral DMARDS
Anti-TNFα
NSAIDS Anti-TNFα Ustekinumab Apremilast Secukinumab
Ustekinumab Apremilast Secukinumab
No Oral DMARDs
Oral DMARDS (MTX, SSZ, HCQ, CSA,
Leflunomide, AZA )
Anti-TNFα
Ustekinumab Apremilast Secukinumab
![Page 21: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/21.jpg)
Cardiovascular Disease Develops Earlier in Psoriatic Arthritis, Psoriasis, and RA
Ogdie A, et al. Ann Rheum Dis 2015;74:326–332
Patient Numbers PsA: 8,706 PsO: 138,424 RA: 41,752 Con: 81,573
![Page 22: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/22.jpg)
PsA and Cardiovascular Disease
• Increased risk of CV death (RR 1.61, 95%CI 1.09-2.38)
• Dyslipidemia that worsens with active disease (↓HDL and↑TG)
• 30% with hypertension
• Obesity, metabolic syndrome, and diabetes are increased
• Increased metabolic syndrome compared to RA [OR 2.44 (95%CI 1.48-4.01)]
• Metabolic syndrome improves with anti-TNF therapy compared to methotrexate alone
Ogdie et al. J. Rheumatol 2014; 41:2315-2322 Costa et al., Clin Rheumatol 2014; 33:833-839
![Page 23: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/23.jpg)
ANCA Vasculitis Update in Treatments
![Page 24: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/24.jpg)
ANCA-Associated Vasculitis • Granulomatosis with polyangiitis (GPA) =Wegener’s
granulomatosis
• Microscopic polyangiitis (MPA)
• Eosinophilic granulomatosis with polyangiitis (EGPA) = Churg-Strauss syndrome
Orbital pseudotumor Crescentic necrotizing
glomerulonephritis
Palate perforation Palpable purpura
![Page 25: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/25.jpg)
Rituximab is Effective for Inducing Remission of ANCA-Associated Vasculitis • Rituximab (anti-B cell antibody) versus oral cytoxan
• RAVE study: double- blinded placebo controlled trial comparing rituximab (375gm/m2 IV weekly for 4 weeks) to cytoxan (2mg/kg per day orally)
• 99 pt assigned to rituximab and 98 to cytoxan
• Rituximab was non-inferior to cytoxan with remission in
63% Rituximab vs 53% cytoxan
• Was superior to cytoxan in severe cases with 67% remission vs 42% with cytoxan
• Rituximab had fewer adverse events (19% vs 32%)
Stone JH et al., NEJM 2010; 363:221-232
![Page 26: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/26.jpg)
Does Rituximab or Azathioprine Maintain ANCA-Vasculitis Remission Better?
Guillevin L et al. N Engl J Med 2014;371:1771-1780.
![Page 27: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/27.jpg)
Rituximab Maintains Remission Better than Azathioprine
All patients in remission with Cytoxan and glucocorticoids Randomly assigned to Rituximab 500mg at 0 and 2 weeks then q 6months versus Azathioprine
![Page 28: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/28.jpg)
ANCA-Vasculitis Treatment
Ntatsaki et al. Rheumatology 2014
![Page 29: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/29.jpg)
PMR Updated Treatment Guidelines
![Page 30: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/30.jpg)
Polymyalgia Rheumatica: Symptoms
• Pain and morning stiffness: • Shoulder and pelvic girdle,
arms, thighs, low back • Symmetrical involvement
• May have mild synovitis • Low grade fever • Weight loss/anorexia • Fatigue • Screen for temporal
arteritis symptoms
• Age>50
• ESR>50
• Shoulder/pelvic pain (no true weakness)
![Page 31: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/31.jpg)
Polymyalgia Rheumatica: Epidemiology
• Age: >50 • Increased incidence with increased age, peaks at 70 • Approaches 1% in the elderly
• Increased in northern European ancestry
• Female: male ratio is 2:1
• Elderly, Caucasian female smokers are highest risk
![Page 32: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/32.jpg)
New PMR Treatment Guidelines
PMR Prednisone 12.5-25mg daily
Clinical response at
4 wks
Taper prednisone to 10mg by
8 wks
Good
Taper Prednisone 1mg/month
Remission Relapse
Increase prednisone back to pre-flare dose
If severe, with synovitis, or unable to take prednisone add
Methotrexate 7.5-10mg weekly
Methotrexate 7.5-10mg/wk
Taper Prednisone more slowly 1mg/2month
Remission
Taper therapy
• Prefer glucocorticoids to NSAIDS • Don’t treat with >30mg a day • Most patients will need treatment for 1-3 years
Arth & Rheum 2015, 67:2569-2580
![Page 33: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/33.jpg)
Quick Pearls
![Page 34: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/34.jpg)
DPP-4 Inhibitors may cause severe joint pain and swelling • Dipeptidyl peptidase-4 inhibitors:
Sitagliptin (Januvia), Saxagliptin (Onglyza), Linagliptin (Tradjenta), and Alogliptin (Nesina)
• Joint pains may occur 1day to years after starting drug
• May mimic new onset rheumatoid arthritis with morning stiffness, swelling, and tenderness
• Arthralgia and mylagia may lead to hospitalization
• Symptoms typically resolve within a month after discontinuation of drug
• Challenge with another DPP-4 may cause recurrence
Tarapues et al. Pharmacoepidemiol Drug Saf. 2013: 1115-8
![Page 35: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/35.jpg)
Epidural Corticosteroids for Radiculopathy and Spinal Stenosis has Minor Benefits
• 400 patients randomized to epidural injections with lidocaine vs lidocaine and glucocorticoids • At 6 wks, both groups had similar improvement in pain and function • The GC group had more adverse events than lidocaine only
• Meta-analysis of 38 placebo controlled trials • Immediate pain reduction was seen with GC compared to control
injection • Benefits were small and not sustained • There was no effect on long-term surgery risk
Friedly JL et al., NEJM 2014; 371:11-21
Chou et al., Ann Int Med 2015; 163:373-381
![Page 36: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/36.jpg)
Scleroderma and Rituximab European Scleroderma Trial and Research (EUSTAR)
• 63 scleroderma (46diffuse, 17limited)
• Rituximab 1000mg IV week 0 and 2 compared to 25 matched controls
Jordan et al. Ann Rheum Dis 2015; 74:1188-94
![Page 37: Update in Rheumatology 2015 - Internal Medicine · Update in Rheumatology 2015 Mary Beth Humphrey, MD, PhD, FACP Professor of Medicine Chief of Rheumatology, Immunology, and Allergy](https://reader030.fdocuments.in/reader030/viewer/2022040516/5e7532921bb4a17e1741da7a/html5/thumbnails/37.jpg)
Thank you!